OmniSeq, the molecular diagnostic testing company of upstate New York's Roswell Park Cancer Institute, is looking for a brand marketing diagnosis.
The Buffalo-based company released an RFP for a marketing and branding agency to review its current structure and handle the task, along with media and digital strategy, going forward.
OmniSeq Target is the flagship product of the company, developed with $20M from the RPCI and another $5M from New York State. The diagnostic test helps doctors customize cancer treatment to individual patients' molecular makeups.
Proposals are due March 31.
A one-year contract is planned. View the RFP (PDF).
Have a comment? Send it to 
No comments have been submitted for this story yet.